In Vitro Diagnostics Business Outlook: Volume 1, Issue 20 - HIV Testing
10 Aug 2022
Categories:
In Vitro Diagnostics Business Outlook
A new twice-monthly publication dedicated to IVD, In Vitro Diagnostics Business Outlook offers the following:
• Market Sizing and Forecasting of IVD Market Segments in Every Issue
• Clinical Chemistry, Infectious Disease Testing, Oncology, Hematology, Blood Banking, Coagulation, Point of Care–Updates on the Important Test Categories You Need to Know About
• Industry Watch – Developments with COVID-19 and Other Testing
• M&A, Distribution, Partnerships Tracked and Charted
• New Product Introductions and Company Announcements
• Company Profiling and Quarterly Results Summaries
• Regional Market Coverage
Table of Contents
-
Market Analysis: HIV Testing
- Overview of HIV
-
Market Outlook
- Major Product Activity
-
Company Briefs
- Bio-Rad
- OraSure Technologies
- Cepheid
- Regional Market
-
Executive News Briefing
- Acuamark Diagnostics Secures Series A Funding
- Invitae Announces New Leadership
- PerkinElmer Announced New Board Member
-
Financial Highlights: Abbott Laboratories, OpGen, QIAGEN
- Abbott Continues Strong Performance in Q2 ’22; Exceeds H1 Expectations, Raises Full Year Guidance
- OpGen Expects 25% to 50% Overall Revenue Growth from Products and Services in 2022
- QIAGEN Reports Non-COVID Sales Growth of 10% in Q2 2022
-
Diagnostic Market Mergers, Acquisitions and Partnership Deals
- Partnerships and Collaborations
- Mergers and Acquisitions
-
Industry Watch
- COVID-19 Update
-
Region Watch
- Canada
- Norway
- Peru
-
Broad-based Company Announcements
- Monkeypox Test Now Available
- Roche Launches Dual Antigen/Antibody Diagnostic Test
- PerkinElmer Tests Added to NICE Diagnostic Guidance